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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: The MFM integrated into the vessel wall while maintaining branch
patency over the course of the study. The 56 thread devices were well tolerated locally
and yielded fewer signs of inﬂammation and neointimal hyperplasia. Further pre-
clinical and clinical studies will extend assessment of the long-term safety and
effectiveness of the MFM.
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Background: Conventional surgical or hybrid repair of aortic arch aneurysms carries
substantial risk of mortality and morbidity. Early experience with custom made
branched arch endografts showed promising results, although availability and pro-
duction time limit their widespread use. Consequently, many patients remain
untreated.This preclinical study is the ﬁrst report of an off-the-shelf modular aortic
arch endograft, with a novel Z shape design addresses the unique procedural and long
term challenges with complete endovascular therapy for aortic arch pathologies.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/NeMethods: Sixteen pigs (7 acute, 9 chronic) underwent endovascular implantation of
the Nexus arch endograft over a brachio-iliac through & through wire technique,
with modular extensions to ascending aorta and LCC. Aggregate follow-up period was
481 days.
Results: Successful implantation of the modular graft was achieved in 100% of an-
imals. Mean procedural time was 9030 Min. Mean pressure gradient between
ascending aorta and cranial vessels was 02 mmHg. All chronic animals recovered
well. Long term follow up demonstrated no graft migration or side branch occlusion/
stenosis.
Conclusions: The novel designed arch endograft (see Figure) has the potential to
provide the next evolutionary step towards an off-the-shelf, pure endovascular
solution as a ﬁrst-line intervention for major aortic arch lesions. The integrated
brachial intra-procedural latching and Brachiocephalic artery placement of a
proximal (cranial) end of the main prosthesis provides the cornerstone for
increased intra-procedural and long term endograft ﬁxation. Initial clinical work
due Q3 2014.
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Background: As ablation and transseptal procedures become more common due to
the aging population, transseptal puncture complications become a larger concern.
Iatrogenic atrial septal defects (IASDs) are typically considered to close within a year
with 7% remaining at 12 months following a puncture with a 12 Fr catheter. Today,
IASDs are also attracting attention because cryoablation and MitraClip procedures
that use larger sheaths are common. The purpose of this experimental paradigm was to
characterize the biomechanical properties of the fossa ovalis in an animal model
commonly used for testing these procedures.
Methods: The atrial septa from Yorkshire Cross swine (n¼86) were excised for
experimentation. The inferior edge of the fossa ovalis was cut off for catheter
tear testing. Samples were randomized to 3 groups, and the transseptal punctures
were performed with a: 1) standard Brockenbrough needle, 2) Baylis RF needle,
or 3) custom RF 5 Fr needle, which was unique design in this study. More
speciﬁcally, catheter tear testing allows for the investigation of the resultant ef-
fects varying catheter sizes and different transseptal approaches have on inducing
trauma.
Results: We observed that the type of needle used for the transseptal puncture
had no statistically signiﬁcant effects on tear forces (p>0.05). This suggests that
on an acute time scale, the procedure a clinician utilized to cross the septum
could be one of personal preference, since no technology demonstrated an in-
crease in tear force and thus a reduction in IASD formation. Yet, there were
signiﬁcant differences in tearing the septum between different size sheaths (p<
0.05). Noteworthy, the forces required to initiate tearing in this study were
within the range of the forces able to be generated by clinically used catheter
and sheaths.
Conclusions: Tissue properties and their role in the formation of IASDs have not been
previously well studied. This suggests a need to improve our basic understanding in
how septa tearing arise and a means to minimize damage created during procedures.
This is the one of the ﬁrst studies performed to investigate a novel transseptal
approach in an effort to minimize IASD formation.
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Background: Polymer coatings of drug eluting stents (DES) have been shown to
offer a protective barrier against acute thrombus formation compared with bare metal
stents (BMS). While this anti-thrombotic function has been assigned to contempo-
rary DES utilizing permanent polymeric coatings, the impact of bioerodible poly-
meric coatings, strut thickness and fully bioresorbable scaffolds remains to be
determined.
Methods: A porcine ex vivo carotid to jugular arterio-venous shunt model
involving a test circuit of three in-line stents, was used to test thrombogenicity.
The Synergy stent (Boston Scientiﬁc) (n¼6) was compared to 3 different
stent types: 1) BioMatrix Flex (Biosensors) 2) BVS (Abbott), and 3)
OmegaTM (Boston Scientiﬁc) (n¼6 each). After 1h of circulation, platelet
adherence in whole mount stents was identiﬁed by immunoﬂuorescent staining
against dual platelet markers (CD61/CD42b) and quantiﬁed using confocal
microscopy.
Results: Synergy DES showed the least area occupied by thrombus compared to
the other 3 stents types, with a signiﬁcant difference compared to BioMatrix Flexw Devices and Innovation B129
